GGrantIndex
Sort

64,565 grants matching drug discovery

Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes

$1,005,177
Brigitte Widemann · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA

Nuclear Factor-kappaB in Ovarian Cancer

$1,005,082
Christina Annunziata · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Defining the Chemical Perturbome of Neural Development and Activity

$1,005,000
Summer B Thyme · Univ Of Massachusetts Med Sch Worcester · DP2 · FY2025 · NS

The Identification and characterization of genetic variants underlying cardiovascular diseases

$1,005,000
Arya Mani · Yale University · R35 · FY2023 · HL

The Identification and characterization of genetic variants underlying cardiovascular diseases

$1,005,000
Arya Mani · Yale University · R35 · FY2018 · HL

The Identification and characterization of genetic variants underlying cardiovascular diseases

$1,005,000
Arya Mani · Yale University · R35 · FY2021 · HL

The Identification and characterization of genetic variants underlying cardiovascular diseases

$1,005,000
Arya Mani · Yale University · R35 · FY2017 · HL

The Identification and characterization of genetic variants underlying cardiovascular diseases

$1,005,000
Arya Mani · Yale University · R35 · FY2019 · HL

The Identification and characterization of genetic variants underlying cardiovascular diseases

$1,005,000
Arya Mani · Yale University · R35 · FY2020 · HL

The Identification and characterization of genetic variants underlying cardiovascular diseases

$1,005,000
Arya Mani · Yale University · R35 · FY2022 · HL

Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models

$1,004,910
William C Hahn · Dana-Farber Cancer Inst · U01 · FY2020 · CA

Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies

$1,004,845
Brian J Druker · Oregon Health & Science University · U01 · FY2017 · CA

Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies

$1,004,844
Brian J Druker · Oregon Health & Science University · U01 · FY2020 · CA

Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies

$1,004,844
Brian J Druker · Oregon Health & Science University · U01 · FY2018 · CA

Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies

$1,004,844
Brian J Druker · Oregon Health & Science University · U01 · FY2021 · CA

Medicinal Chemistry Core

$1,004,802
John Schneekloth · Division Of Basic Sciences - Nci · ZIC · FY2023 · CA

Development Of Theoretical Methods For Studying Biological Macromolecules

$1,004,608
Bernard R Brooks · National Heart, Lung, And Blood Institute · ZIA · FY2022 · HL

Targeting the checkpoint regulator VISTA for treatment of inflammatory disease

$1,004,563
Jay L Rothstein · Immunext, Inc. · R44 · FY2019 · AI

Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program.

$1,004,351
Hugh William Alsop · Kinoxis Therapeutics Pty Ltd · UH3 · FY2024 · DA

Development of ultra-efficient antibodies for single cell mapping applications

$1,004,302
Andrea Lynn Johnstone · Epicypher, Inc. · R44 · FY2025 · AI

Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy

$1,004,278
Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2019 · CA

Imaging Probe Development Center

$1,004,245
Rolf Swenson · National Heart, Lung, And Blood Institute · ZIC · FY2019 · HL

Rational design of bifunctional protein degrader drugs

$1,004,186
Karteek Kadimisetty · Lifesensors, Inc. · R44 · FY2021 · GM

SRI TO 13 - CONTINUOUS RODENT AND NON-RODENT PHARMACOKINETIC ASSESSMENTS

$1,003,731
Carol Green · Sri International · N01 · FY2024 · DA

Antifibrotic Therapy for Chronic Kidney Disease

$1,002,967
Prakash Narayan · Angion Biomedica Corporation · R44 · FY2013 · DK